The first batch of Russia's Sputnik V vaccine for COVID-19 is likely to reach Kanpur's Ganesh Shankar Vidyarthi Medical College by next week wherein the vaccine's Phase 2 and Phase 3 human clinical trials will be conducted.
The decision to conduct the human clinical trials of the vaccine was taken after Dr Reddy's Laboratories got approval from the Drugs Controller General of India (DCGI) in this regard, an official said.
Speaking to PTI, college principal R B Kamal said the human clinical trials of the vaccine will start from next week.
"As many as 180 volunteers have registered for the trials. Head of the research Saurabh Agarwal will determine the dosage of the vaccine to be administered. One dose will be administered and the condition of volunteers will be monitored to determine whether they need further doses or not," he said.
Kamal said the volunteers' vitals and condition will be checked periodically and the data will be analysed to determine whether the vaccine is a success or not.
He said the effect of the vaccine on the volunteers will be studied for seven months after the same is administered once, twice or thrice within an interval of 21 days.
After observing the effects of the vaccine for a month, authorities will be apprised of the results of the trial and they will then make a decision accordingly.
The Ethics Committee of the college has also given permission for the trails, he said.
The vaccine has to be kept at a temperature of -20 to -70 degrees Celsius.
In September, Dr Reddy's and the Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.
As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr Reddy's upon regulatory approval in India.
On August 11, the Sputnik V vaccine was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vector platform.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU